KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $686.0 million.

  • Teva Pharmaceutical Industries' Income towards Parent Company rose 34326.24% to $686.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $686.0 million, marking a year-over-year increase of 34326.24%. This contributed to the annual value of $1.4 billion for FY2025, which is 17112.35% up from last year.
  • Teva Pharmaceutical Industries' Income towards Parent Company amounted to $686.0 million in Q4 2025, which was up 34326.24% from $428.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Income towards Parent Company's 5-year high stood at $686.0 million during Q4 2025, with a 5-year trough of -$2.4 billion in Q4 2023.
  • Moreover, its 5-year median value for Income towards Parent Company was -$744.5 million (2021), whereas its average is -$747.3 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first crashed by 11153.42% in 2022, then skyrocketed by 34326.24% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Income towards Parent Company (Quarter) stood at -$1.1 billion in 2021, then plummeted by 90.51% to -$2.1 billion in 2022, then decreased by 13.53% to -$2.4 billion in 2023, then soared by 88.33% to -$282.0 million in 2024, then surged by 343.26% to $686.0 million in 2025.
  • Its last three reported values are $686.0 million in Q4 2025, $428.0 million for Q3 2025, and $274.0 million during Q2 2025.